Repligen slides 8.3% as CEO share sale disclosure weighs on sentiment

Repligen Corporation (RGEN) is down 8.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The drop appears tied to a newly disclosed insider sale by Repligen’s CEO, which can pressure shares by signaling near-term caution (even when sales are pre-planned). The move may have been amplified by a risk-off reaction ahead of the company’s next earnings report and lingering sensitivity to 2026 guidance.

Details:

A Form 4 filing disclosed that CEO Olivier Loeillot sold shares on April 21, 2026, with the transaction filed on April 22, 2026.

The filing shows 3,832 shares sold at about $140.00 per share (roughly $536k total), a size that can still affect sentiment in a stock with recent volatility.

Repligen previously issued FY2026 guidance (including revenue and adjusted EPS ranges) that investors have been watching closely for signs of bioprocessing demand recovery.

The company has scheduled its next quarterly earnings release for May 5, 2026, which can increase short-term positioning and profit-taking.

Sources:

U.S. SEC (EDGAR), Repligen Investor Relations, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$RGEN Insider Trading Activity

$RGEN insiders have traded $RGEN stock on the open market 16 times in the past 6 months. Of those trades, 0 have been purchases and 16 have been sales.

Here’s a breakdown of recent trading of $RGEN stock by insiders over the last 6 months:

ANTHONY HUNT has made 0 purchases and 12 sales selling 45,000 shares for an estimated $7,014,218.
OLIVIER LOEILLOT (Chief Executive Officer) has made 0 purchases and 2 sales selling 10,873 shares for an estimated $1,733,450.
JAMES BYLUND (Chief Operating Officer) sold 2,191 shares for an estimated $331,301
KAREN A DAWES sold 275 shares for an estimated $44,275

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

EARLY ACCESS

Receive RGEN Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$RGEN Hedge Fund Activity

We have seen 209 institutional investors add shares of $RGEN stock to their portfolio, and 225 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

WASATCH ADVISORS LP added 1,243,531 shares (+inf%) to their portfolio in Q1 2026, for an estimated $146,512,822
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ added 1,215,527 shares (+inf%) to their portfolio in Q4 2025, for an estimated $199,176,254
PRICE T ROWE ASSOCIATES INC /MD/ added 1,091,683 shares (+31.1%) to their portfolio in Q4 2025, for an estimated $178,883,176
RTW INVESTMENTS, LP added 1,064,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $174,347,040
FRANKLIN RESOURCES INC added 677,146 shares (+159.6%) to their portfolio in Q4 2025, for an estimated $110,957,143
BALYASNY ASSET MANAGEMENT L.P. removed 652,186 shares (-85.0%) from their portfolio in Q4 2025, for an estimated $106,867,197
FRED ALGER MANAGEMENT, LLC added 553,105 shares (+154.3%) to their portfolio in Q4 2025, for an estimated $90,631,785

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$RGEN Congressional Stock Trading

Members of Congress have traded $RGEN stock 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $RGEN stock by members of Congress over the last 6 months:

REPRESENTATIVE LISA C. MCCLAIN has traded it 3 times. They made 1 purchase worth up to $15,000 on 10/30 and 2 sales worth up to $30,000 on 10/31, 10/30.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$RGEN Analyst Ratings

Wall Street analysts have issued reports on $RGEN in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Barclays issued a "Overweight" rating on 10/29/2025

To track analyst ratings and price targets for $RGEN, check out Quiver Quantitative's $RGEN forecast page.

$RGEN Price Targets

Multiple analysts have issued price targets for $RGEN recently. We have seen 7 analysts offer price targets for $RGEN in the last 6 months, with a median target of $160.0.

Here are some recent targets:

Kyle Mikson from Canaccord Genuity set a target price of $145.0 on 04/20/2026
Natalya Davies from Roth Capital set a target price of $160.0 on 04/17/2026
Luke Sergott from Barclays set a target price of $145.0 on 04/14/2026
Daniel Markowitz from Evercore ISI Group set a target price of $140.0 on 04/06/2026
Raghuram Selvaraju from HC Wainwright & Co. set a target price of $208.0 on 03/23/2026
Brandon Couillard from Wells Fargo set a target price of $180.0 on 02/25/2026
Dan Leonard from UBS set a target price of $195.0 on 02/25/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.